Revision as of 19:37, 5 October 2014

The AcCELLerator

The Vector

Introduction

We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.

Stable integration

Our viral vector derives from the murine leukemia virus and since this virus is a retrovirus, it stably integrate the gene of interest into the target genomes. Any gene of interest can be delivered. We demonstrated the capability of stable gene integration by creating an EGFP cell line by infecting murine cells with our viral vector. Two days after virus infection, we selected for cells displaying green fluorescence by a cell sorter. Afterwards, we analyzed the EGFP cell line for several weeks by flow cytometry. Sustained expression of EGFP indicates stable integration into the genome of the original cell line.

Fig.: Transduction efficiency of the viral vector in mouse cells.

bla bla

High efficiency

The vector we use transfers genes into target genomes. We increased the efficiency in cell targeting and gene transfer to reach an infection rate of over 80% in murine cell lines and high infection rates in other cell lines expressing the murine CAT-1 receptor. Protocols for virus production and target cell transduction were optimized. As producer cell line for viral particles we took Phoenix cells containing plasmids with viral genes. Before transfection with the pMIG, we split Phoenix cells several times to increase viability and bring them into the exponential growth phase during production on the viral vector. In addition, supernatant containing the vector were harvest at distinct time points optimized for optimal viral titer. Target cells were infected by viral supernatant with Polybrene which increases the probability for particle to reach their target cells. Since murine leukemia viruses only infect dividing cells, the growth phase of the target cells were adjusted to the time point of infection. Under these optimized conditions, the efficiency for infecting murine cell lines with our viral vector was over 80%. Since we had only 16% transduction efficiency at the beginning of the project, we would consider this a significant advance. To our knowledge, an optimized infection protocol with murine leukemia virus has not been published to date. The exact procedure can be found here (link).

Fig.: nice pictures of nice cells.

Fig.: Transduction efficiency of the viral vector in mouse cells.

With the viral vector used in our system transduction efficiency in murine cells was optimized to almost 100%!

Fig.: Concentrated virus

blubb!

Specificity and safety of MuLV

An important aspect for the function of our system as well as for its safety is the specificity of the vector regarding infection of different kind of cells. The vector deriving from the murine leukemia virus is specific for cells carrying the mouse specific CAT-1. Cells that do not have this specific receptor are not targeted by the vector. In order to test the specificity of the system, different kind of cells were incubated with the vector containing EGFP. Since EGFP is stable integrated by the system, infected cells are identified by a green fluorescence that was analysed via flow cytometry (figure 1).

We tested two human cell lines, human embryonic kidney cells as well as human lung epithel carcinoma cells, for their capability of being targeted by the vector. In addition, mouse fibroblasts that express the mouse specific CAT-1 receptor were tested for a positive control. As shown in figure 1 both human cell lines did not express EGFP after incubation with the vector indicating that they were not targeted. However, many cells of the mouse cell line were expressing EGFP after infection.

Fig.1: Description of the experiment (as picture)

Fig.X: FACS analysis of different cell lines incubated with the CAT-1 specific viral vector

Left: Different cell lines not incubated with the vector as negative control, Middle: different cell lines infected with MuLV IRES EGFP (50% in completed growth medium), Right: cells transfected with the mouse specific receptor CAT-1 (rz006) were infected with the viral vector. The infection efficiency is directly correlated with transfection efficiency of the receptor into the different kind of cells.

Fig.1: Infection of different cell lines with the viral vector derived from the murine leukemia virus.

In order to investigate the specificity of the viral vector, two human cell lines, human embryonic kidney cells as well as lung epithel carcinoma cells, were infected and the percentage of cells expressing EGFP was analyzed by flow cytometry.

The vector derived from the murine leukemia virus is specific for the murine CAT-1 receptor. Therefore it is not able to infect human cell lines!

Retrieved from "http://2014.igem.org/Team:Freiburg/Content/Results/Vector"

@@ Line 10: / Line 10: @@
 	<div class="row category-row">
 		<div class="col-sm-6">
-			<p>For stable integration of genes into the genome of target cells we use a vector derived from the murine leukemia virus. The advantages of this vector are its specificity making the viral work safe and easy, its high efficiency for infecting target cells and the ability of stable gene transfer into target genomes. The following results prove these qualities of this part of the system.</p>
+			<p>We succeed to stably integrate our gene of interest into the genome of target cells by using a viral vector derived from the murine leukemia virus. The advantages of this vector are: its specificity for murine cells, making the viral work safe and easy; a very high efficiency for infection; and the ability of stable gene transfer into the genomes of target cells. Here we present results on these three qualities of our viral vector and how we optimized virus production and cell infection.</p>
 		</div>
 		<div class="col-sm-6">
@@ Line 28: / Line 28: @@
 		<div class="col-sm-6">
 		<p>
-		Our vector derives from the murine leukemia virus. Since this virus is kind of a retrovirus, it can stable integrate genes into target genomes. Depending on what oligonucleotides are included in the viral particle any gene of interest can be delivered. We have proven the capability of stable integration by creating a cell line infecting murine cells with our viral vector. The vector was designed to deliver a gene for EGFP into target cells. Cells that were infected with the viral particles were identified by expressing EGFP and sorted for green fluorescence by a cell sorter. Analysis by flow cytometry of our created cell line reveals that the capability for EGPF expression is not getting lost after several rounds of splitting indicating a stable integration of this gene.
+		Our viral vector derives from the murine leukemia virus and since this virus is a retrovirus, it stably integrate the gene of interest into the target genomes. Any gene of interest can be delivered. We demonstrated the capability of stable gene integration by creating an EGFP cell line by infecting murine cells with our viral vector. Two days after virus infection, we selected for cells displaying green fluorescence by a cell sorter. Afterwards, we analyzed the EGFP cell line for several weeks by flow cytometry. Sustained expression of EGFP indicates stable integration into the genome of the original cell line.
 		</p>
 		</div>
@@ Line 70: / Line 70: @@
 	<div class="row category-row">
 		<div class="col-sm-6">
-		<p>The vector we use transfers genes into target genomes. We raised the efficiency in cell targeting and gene transfer to reach an infection rate of almost 100% in murine cell lines and high infection rates in other cell lines expressing the murine CAT-1 receptor. Therefore, we optimized protocols for virus production and for transducing target cells. Phoenix cells, our producer cell line, were split several times before usage to make sure	to have them healthy and in an exponential growth phase during the production of viral particles. In addition, supernatant containing the vector were harvest at distinct time points optimized for optimal viral titer. Target cells were infected by viral supernatant with Polybrene that raises	the probability for particle to reach their target cells. Since murine leukemia viruses only infect dividing cells, growth phases of target cells were adapted to infection. Last of all, the proportion of viral supernatant to growth medium during infection was optimized to ensure exponential	growth and health of target cells. Considering all these aspects we reached almost enormous high efficiency in infecting murine cell lines with our viral vector. Since we had only 16% efficiency in transferring genes with the vector at the beginning of the projekt, we increased the.</p>
+		<p>The vector we use transfers genes into target genomes. We increased the efficiency in cell targeting and gene transfer to reach an infection rate of over 80% in murine cell lines and high infection rates in other cell lines expressing the murine CAT-1 receptor. Protocols for virus production and target cell transduction were optimized. As producer cell line for viral particles we took Phoenix cells containing plasmids with viral genes. Before transfection with the pMIG, we split Phoenix cells several times to increase viability and bring them into the exponential growth phase during production on the viral vector. In addition, supernatant containing the vector were harvest at distinct time points optimized for optimal viral titer. Target cells were infected by viral supernatant with Polybrene which increases the probability for particle to reach their target cells. Since murine leukemia viruses only infect dividing cells, the growth phase of the target cells were adjusted to the time point of infection. Under these optimized conditions, the efficiency for infecting murine cell lines with our viral vector was over 80%. Since we had only 16% transduction efficiency at the beginning of the project, we would consider this a significant advance. To our knowledge, an optimized infection protocol with murine leukemia virus has not been published to date. The exact procedure can be found here (link).
 		</div>
 		<div class="col-sm-6">